A
Annemarie R. Thornton
Researcher at Merck & Co.
Publications - 2
Citations - 2074
Annemarie R. Thornton is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cervical intraepithelial neoplasia & Population. The author has an hindex of 2, co-authored 2 publications receiving 1998 citations.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal ArticleDOI
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Ole Eric Iversen,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Hseon Tay Eng,F. Xavier Bosch,Joakim Dillner,Sven Eric Olsson,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Teresa M. Hesley,Micki Nelson,Radha Railkar,Margaret James,Carlos Sattler,Frank J. Taddeo,Annemarie R. Thornton,Scott Vuocolo +33 more
TL;DR: In this article, the quadrivalent human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, 11, 16, and 18 in 16-26-year-old women naive for HPV vaccine types.